MK-1454-002
16 Dec 2020
MK-1454-002
NCT04220866
A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination With IV Pembrolizumab vs IV Pembrolizumab Monotherapy
Merck Sharp & Dohme Corp.
Cancer Type | Head and Neck |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | Head and neck squamous cell carcinoma |
Cancer Stage | Metastatic or Widespread |
Anticipated Start Date | 2020-03-04 |
Anticipated End Date | 2023-09-28 |
Hospital | Calvary Central Districts Hospital |
---|---|
Clinical Trial Coordinator | Julie Rowe |
julie.rowe@calvarycare.org.au | |
Phone | 08 8239 9536 |
Principal Investigator | Dr Rohit Joshi |
Recruitment Status | Recruiting |